-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8

Benzinga·03/18/2026 13:17:22
Listen to the news
UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $7 to $8.